VNDA

Vanda Pharmaceuticals (VNDA)

Vanda Pharmaceuticals Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:VNDA

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/10	06 : 15	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/05/09	20 : 07	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/05/09	05 : 06	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/05/09	05 : 01	PR Newswire (US)	Vanda Pharmaceuticals Reports First Quarter 2024 Financial Results	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/05/08	05 : 51	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/05/08	00 : 16	PR Newswire (US)	Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future Pak	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/05/01	05 : 30	PR Newswire (US)	Vanda Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 8, 2024	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/04/25	21 : 05	GlobeNewswire Inc.	Shareholder Capital Delivers Letter to Independent Members of the Board of Vanda Pharmaceuticals	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/04/23	08 : 13	PR Newswire (US)	Vanda Pharmaceuticals Reacts to U.S. Supreme Court's Denial of its Petition in HETLIOZ® ANDA Litigation	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/04/17	23 : 21	PR Newswire (US)	Vanda Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/04/17	22 : 02	PR Newswire (US)	Vanda Pharmaceuticals Confirms Rejection of Unsolicited Takeover Proposals from Future Pak	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/04/03	23 : 25	AllPennyStocks.com	Biotech Catches Major Premarket Bid Following FDA Approval	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/04/03	07 : 10	PR Newswire (US)	Vanda Pharmaceuticals' Fanapt® (iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorder	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/03/08	06 : 31	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/03/07	06 : 50	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/03/07	06 : 48	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/03/07	06 : 47	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/03/07	06 : 46	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/03/07	06 : 46	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/03/06	21 : 00	PR Newswire (US)	Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/03/05	11 : 14	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/03/05	11 : 12	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/03/05	11 : 10	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/03/05	11 : 08	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/03/05	11 : 06	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/02/22	06 : 53	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/02/22	06 : 52	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/02/22	06 : 52	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/02/22	06 : 52	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VNDA	Vanda Pharmaceuticals Inc
2024/02/22	06 : 50	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VNDA	Vanda Pharmaceuticals Inc